EUVIMEDEUVIMED entdecken
Crossref

A DNAzyme‐Based Nanohybrid for Ultrasound and Enzyme Dual‐Controlled mRNA Regulation and Combined Tumor Treatment

Hanji Huang, Yaoxuan Chen, Lele Li iD, Li Zheng

Advanced Materials · 2024-12 · 36 (50)

DOI: 10.1002/adma.202409035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 29.10.2024. Verfasst von Hanji Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Guangxi Engineering Center in Biomedical Materials for Tissue and Organ Regeneration, Collaborative Innovation Centre of Regenerative Medicine and Me…. Hauptthemen laut MEDLINE: DNA, Catalytic, RNA, Messenger. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the significant potential of RNA‐cleaving DNAzymes for gene regulation, their application is limited by low therapeutic efficacy and lack of cell‐specific control. Here, a DNAzyme‐based nanohybrid designed for ultrasound (US)‐controlled, enzyme‐activatable mRNA regulation is presented, enabling tumor cell‐selective combination therapy. The nanohybrid is constructed by coordination‐directed self‐assembly of an enzymatically‐triggerable therapeutic DNAzyme (En‐Dz) and natural sonosensitizer hemoglobin (Hb). Controlled US exposure induces reactive oxygen species generation from Hb units, which not only facilitates efficient endosomal escape of En‐Dz, but also promotes the translocation of specific enzyme from the nucleus to the cytoplasm, thereby enhancing gene regulation efficacy. Notably, the enzyme‐triggered, spatiotemporally‐controlled activation of En‐Dz's catalytic activity results in enhanced cancer‐cell selectivity in the therapeutic treatment. Furthermore, the combination of enzyme‐activated mRNA regulation and sonodynamic therapy significantly enhances anti‐tumor efficacy both in vitro and in vivo. This work highlights the potential of integrating a sonodynamic strategy to overcome the current limitations of DNAzyme‐based gene regulators, providing a spatiotemporally‐controlled approach for precise tumor treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA, CatalyticRNA, MessengerHumansAnimalsCell Line, TumorNeoplasmsMiceReactive Oxygen SpeciesUltrasonic TherapyHemoglobinsNanoparticlesCombined Modality TherapyUltrasonic Waves

Stichwörter der Autor:innen

DNAzymecombinational therapygene regulationnanohybridultrasound control

Substanzen

DNA, CatalyticRNA, MessengerReactive Oxygen SpeciesHemoglobins

Autor:innen und Institutionen

  • Guangxi Engineering Center in Biomedical Materials for Tissue and Organ Regeneration, Collaborative Innovation Centre of Regenerative Medicine and Medical BioResource Development and Application, Guangxi Key Laboratory…
  • CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Beijing, 100190, China.

ORCID-Profile: Lele Li

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Huang, H., Chen, Y., Li, L., & Zheng, L. (2024). A DNAzyme‐Based Nanohybrid for Ultrasound and Enzyme Dual‐Controlled mRNA Regulation and Combined Tumor Treatment. Advanced Materials, 36(50). https://doi.org/10.1002/adma.202409035

Vancouver

Huang H, Chen Y, Li L, Zheng L. A DNAzyme‐Based Nanohybrid for Ultrasound and Enzyme Dual‐Controlled mRNA Regulation and Combined Tumor Treatment. Advanced Materials. 2024;36(50). doi:10.1002/adma.202409035

BibTeX
@article{Huang2024,
  author = {Huang, Hanji and Chen, Yaoxuan and Li, Lele and Zheng, Li},
  title = {A DNAzyme‐Based Nanohybrid for Ultrasound and Enzyme Dual‐Controlled mRNA Regulation and Combined Tumor Treatment},
  journal = {Advanced Materials},
  year = {2024},
  volume = {36},
  number = {50},
  doi = {10.1002/adma.202409035}
}
Kostenlos starten →